188 TREATMENT OF CARCINOMA IN SITU OF THE BLADDER ASSOCIATED OR NOT ASSOCIATED TO NON-MUSCLE INVASIVE TRANSITIONAL CARCINOMA USING TWO DIFFERENT BCG DOSES: THE STANDARD OR ONE-THIRD DOSE. A FIVE YEAR FOLLOW-UP